Executive Summary

37 complainants and six private plaintiffs directly harmed by mRNA “vaccinations” file present criminal complaints to protect their own health and out of legitimate concern for the health of their fellow human beings.

In the present case, we are dealing with the most serious threat to human health caused by pharmaceuticals and the most serious injury to human health that has ever occurred in Switzerland: The approval and administration of the largely ineffective mRNA “vaccines” pose a far greater threat than the SARS-CoV-2 pathogen from which these “vaccines” are supposed to protect.

Swissmedic is primarily responsible for this threat: By law, it has the central function of protecting the health of the Swiss population. To this end, it must ensure, on the one hand, that only high quality, safe, and effective ther-apeutic products are placed on the market. On the other hand, it must protect consumers of therapeutic products against fraud (Art. 1 TPA). The notifying parties acting on behalf of Swissmedic failed to comply with these guarantee obligations on several occasions and to a significant extent, which is why they have been under strong suspicion, since December 2020 and up to the present day,

• of having repeatedly violated the due diligence obligations under therapeutic product law (Art. 86(1a) TPA, in conjunction with. Art. 3 TPA and Art. 7 TPA) in the course of marketing au-thorization and batch testing which, according to federal court rulings, is deemed to be manufacturing,
• of not having fulfilled the duty of post-marketing surveillance (so-called «pharmacovigi-lance») in a risk-adequate manner, but rather having permanently violated the obligation to notify under therapeutic product law (Art. 87(1c) TPA) in a serious manner,
• of having seriously violated the prohibition on the advertising of therapeutic products (Art. 87(1b) TPA),
• of having satisfied the corresponding elements of an offense under the Criminal Code when a «success» (death, bodily injury) has occurred.

The breaches of due diligence obligations complained of here essentially consist in the fact that the notifying parties acting on behalf of Swissmedic (and, in principle, also the notified physicians) were already aware of countless risk factors from December 2020 onwards, each of which, when assessed in isolation, would have prevented the granting of the «temporary» authorization (and the administration of the corresponding mRNA injec-tions) until the corresponding risk factors had been clarified in detail and eliminated under normal circumstances.

The following should be highlighted here…

Read more here: